Success Metrics

Clinical Success Rate
100.0%

Based on 21 completed trials

Completion Rate
100%(21/21)
Active Trials
0(0%)
Results Posted
100%(21 trials)

Phase Distribution

Ph phase_4
1
5%
Ph phase_2
5
23%
Ph phase_3
16
73%

Phase Distribution

0

Early Stage

5

Mid Stage

17

Late Stage

Phase Distribution22 total trials
Phase 2Efficacy & side effects
5(22.7%)
Phase 3Large-scale testing
16(72.7%)
Phase 4Post-market surveillance
1(4.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

95.5%

21 of 22 finished

Non-Completion Rate

4.5%

1 ended early

Currently Active

0

trials recruiting

Total Trials

22

all time

Status Distribution
Completed(21)
Terminated(1)

Detailed Status

Completed21
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
22
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 25 (22.7%)
Phase 316 (72.7%)
Phase 41 (4.5%)

Trials by Status

completed2195%
withdrawn15%

Recent Activity

Clinical Trials (22)

Showing 20 of 22 trialsScroll for more
NCT01715311Phase 4

Comparison of Indacaterol With That of Placebo in 'Maintenance naïve' Patients With COPD Using Blinded Tiotropium as Active Control

Withdrawn
NCT00927901Phase 2

Efficacy, Safety, Tolerability, and Pharmacokinetics of Indacaterol Salts in Patients With Asthma

Completed
NCT00557466Phase 2

A Dose Ranging Trial of 4 Doses of Indacaterol Delivered Via the TWISTHALER® Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Completed
NCT00545272Phase 2

A Dose Ranging Trial of 4 Doses of Indacaterol Delivered Via TWISTHALER® Device in Adult and Adolescent Patients With Persistent Asthma

Completed
NCT00669617Phase 3

Study to Determine the Onset of Action of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Completed
NCT00529529Phase 3

Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma

Completed
NCT00877383Phase 3

Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease

Completed
NCT01068600Phase 3

Comparison of Efficacy of Indacaterol Versus Placebo Over 12 Weeks

Completed
NCT01079130Phase 3

Efficacy and Safety of Different Doses of Indacaterol

Completed
NCT01072448Phase 3

12-week Efficacy of Indacaterol

Completed
NCT01089127Phase 3

Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD)

Completed
NCT00900731Phase 3

A Study to Compare the Lung Effect of Indacaterol and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD)

Completed
NCT00463567Phase 2

26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Completed
NCT00846586Phase 3

Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease

Completed
NCT00393458Phase 3

Efficacy, Safety, and Tolerability of Once Daily Indacaterol in Chronic Obstructive Pulmonary Disease (COPD) Using Formoterol Twice Daily as Active Control

Completed
NCT00821093Phase 3

Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD)

Completed
NCT00567996Phase 3

Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Using Salmeterol as Active Control

Completed
NCT00622635Phase 3

A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

Completed
NCT00624286Phase 3

Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Completed
NCT00615030Phase 3

Study of Indacaterol Dosed in the Evening in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Completed

Drug Details

Intervention Type
DRUG
Total Trials
22